Peer-reviewed veterinary case report
Predicting death risk in dogs with mast cell tumors using clinical
By Horta, Rodrigo S et al.·Published in Veterinary pathology·2018·1 Universidade Vila Velha, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features.
- Species:
- dog
Plain-English summary
A study looked at 149 dogs with mast cell tumors (MCT), a type of skin cancer, to find out which factors could predict how likely they were to survive. The researchers found that dogs with a history of tumor recurrence and those classified using an updated staging system had a higher risk of death. This means that if your dog has had a mast cell tumor before or if the tumor is at a more advanced stage, it may be more serious. The study suggests using this new staging method to better assess the risk and guide treatment options for dogs with MCT.
People also search for: dog mast cell tumor prognosis · mast cell tumor treatment for dogs · dog skin cancer survival rate
Abstract
Mast cell tumor (MCT) is a frequent cutaneous neoplasm in dogs that is heterogeneous in clinical presentation and biological behavior, with a variable potential for recurrence and metastasis. Accurate prediction of clinical outcomes has been challenging. The study objective was to develop a system for classification of canine MCT according to the mortality risk based on individual assessment of clinical, histologic, immunohistochemical, and molecular features. The study included 149 dogs with a histologic diagnosis of cutaneous or subcutaneous MCT. By univariate analysis, MCT metastasis and related death was significantly associated with clinical stage ( P < .0001, r= -0.610), history of tumor recurrence ( P < .0001, r= -0.550), Patnaik ( P < .0001, r= -0.380) and Kiupel grades ( P < .0001, r= -0.500), predominant organization of neoplastic cells ( P < .0001, r= -0.452), mitotic count ( P < .0001, r= -0.325), Ki-67 labeling index ( P < .0001, r= -0.414), KITr pattern ( P = .02, r= 0.207), and c-KIT mutational status ( P < .0001, r= -0.356). By multivariate analysis with Cox proportional hazard model, only 2 features were independent predictors of overall survival: an amendment of the World Health Organization clinical staging system (hazard ratio [95% CI]: 1.824 [1.210-4.481]; P = .01) and a history of tumor recurrence (hazard ratio [95% CI]: 9.250 [2.158-23.268]; P < .001]. From these results, we propose an amendment of the WHO staging system, a method of risk analysis, and a suggested approach to clinical and laboratory evaluation of dogs with cutaneous MCT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29338615/